ODTX
Odyssey Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.70
+8.71%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.6x
Market Cap
$1.38B
MomentumView details →
1D Return
+8.71%
YTD Return
—
RSI (14)
68.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.6x
Market Cap
$1.38B
RSI (14)
68.5
MomentumView details →
1D Return
+8.71%
YTD Return
—
Similar companies
Latest newsMore news →
Evotec SE announced a strategic R&D collaboration with Odyssey Therapeutics to discover new treatments for autoimmune and inflammatory diseases using Evotec's AI-enabled discovery platform.30d agoOdyssey Therapeutics reported a GAAP net loss of $52.8 million for Q2 2026, compared to a net loss of $41.2 million in Q2 2025, with cash and marketable securities of $433.1 million as of June 30, 2026.32d ago